Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Marcela Guadalupe del Carmen, M.D.

Co-Author

This page shows the publications co-authored by Marcela del Carmen and Neil Horowitz.
Connection Strength

2.830
  1. Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery. Gynecol Oncol. 2017 12; 147(3):612-616.
    View in: PubMed
    Score: 0.182
  2. Investigating the Impact of Body Mass Index on Intraperitoneal Chemotherapy Outcomes in Ovarian and Fallopian Tube Cancer. Int J Gynecol Cancer. 2016 07; 26(6):1033-40.
    View in: PubMed
    Score: 0.167
  3. Clinical characteristics and outcomes of patients with stage I epithelial ovarian cancer compared with fallopian tube cancer. Am J Obstet Gynecol. 2015 May; 212(5):600.e1-8.
    View in: PubMed
    Score: 0.150
  4. Comparison of outcomes in patients with early-stage mucinous endometrial cancer and those with endometrioid endometrial cancer, with and without adjuvant therapy. J Reprod Med. 2014 Nov-Dec; 59(11-12):527-33.
    View in: PubMed
    Score: 0.149
  5. Endometrial stromal sarcoma: a clinicopathologic study of 29 patients. J Reprod Med. 2014 Nov-Dec; 59(11-12):547-52.
    View in: PubMed
    Score: 0.149
  6. What is the optimal treatment for obese patients with advanced ovarian carcinoma? Am J Obstet Gynecol. 2014 Sep; 211(3):231.e1-9.
    View in: PubMed
    Score: 0.143
  7. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol. 2014 Mar; 132(3):760-6.
    View in: PubMed
    Score: 0.141
  8. Prognostic determinants in patients with uterine and ovarian carcinosarcoma. J Reprod Med. 2013 Jul-Aug; 58(7-8):297-304.
    View in: PubMed
    Score: 0.136
  9. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecol Oncol. 2013 Apr; 129(1):63-8.
    View in: PubMed
    Score: 0.132
  10. Prognostic determinants in patients with stage I uterine papillary serous carcinoma: a 15-year multi-institutional review. Int J Gynecol Cancer. 2012 Mar; 22(3):417-24.
    View in: PubMed
    Score: 0.124
  11. Prognostic determinants in patients with uterine and ovarian clear carcinoma. Gynecol Oncol. 2012 May; 125(2):376-80.
    View in: PubMed
    Score: 0.124
  12. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 May; 125(2):362-6.
    View in: PubMed
    Score: 0.123
  13. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011 Jun 01; 121(3):477-81.
    View in: PubMed
    Score: 0.116
  14. Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma. Gynecol Oncol. 2010 Nov; 119(2):299-304.
    View in: PubMed
    Score: 0.111
  15. A comparison of outcome in patients with stage 1 clear cell and grade 3 endometrioid adenocarcinoma of the endometrium with and without adjuvant therapy. Eur J Gynaecol Oncol. 2010; 31(3):284-7.
    View in: PubMed
    Score: 0.106
  16. Demographic, risk factor, and knowledge differences between Latinas and non-Latinas referred to colposcopy. Gynecol Oncol. 2007 Jan; 104(1):70-6.
    View in: PubMed
    Score: 0.085
  17. Impact of residual disease at interval debulking surgery on platinum resistance and patterns of recurrence for advanced-stage ovarian cancer. Int J Gynecol Cancer. 2021 10; 31(10):1341-1347.
    View in: PubMed
    Score: 0.060
  18. Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. Ann Surg Oncol. 2021 Oct; 28(11):6705-6713.
    View in: PubMed
    Score: 0.058
  19. Neoadjuvant chemotherapy does not disproportionately influence post-operative complication rates or time to chemotherapy in obese patients with advanced-stage ovarian cancer. Gynecol Oncol. 2020 12; 159(3):687-691.
    View in: PubMed
    Score: 0.056
  20. Use of ablation and ultrasonic aspiration at primary debulking surgery in advanced stage ovarian, fallopian tube, and primary peritoneal cancer. Int J Gynecol Cancer. 2020 07; 30(7):1052-1057.
    View in: PubMed
    Score: 0.055
  21. Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer. Gynecol Oncol. 2020 06; 157(3):700-705.
    View in: PubMed
    Score: 0.054
  22. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome. Am J Obstet Gynecol. 2019 10; 221(4):326.e1-326.e7.
    View in: PubMed
    Score: 0.051
  23. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma. Int J Gynecol Cancer. 2019 03; 29(3):585-592.
    View in: PubMed
    Score: 0.050
  24. Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter? Gynecol Oncol. 2019 04; 153(1):63-67.
    View in: PubMed
    Score: 0.050
  25. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery? Gynecol Oncol. 2018 08; 150(2):233-238.
    View in: PubMed
    Score: 0.048
  26. Patient, treatment and discharge factors associated with hospital readmission within 30days after surgery for vulvar cancer. Gynecol Oncol. 2017 Jan; 144(1):136-139.
    View in: PubMed
    Score: 0.043
  27. Management and outcome of cervical cancer diagnosed in pregnancy. Am J Obstet Gynecol. 2017 03; 216(3):276.e1-276.e6.
    View in: PubMed
    Score: 0.043
  28. Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis. Gynecol Oncol. 2014 May; 133(2):216-20.
    View in: PubMed
    Score: 0.035
  29. Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Sep; 23(7):1219-25.
    View in: PubMed
    Score: 0.034
  30. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer. Ann Surg Oncol. 2012 Mar; 19(3):959-65.
    View in: PubMed
    Score: 0.030
  31. Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer. BJOG. 2010 Jan; 117(1):32-8.
    View in: PubMed
    Score: 0.027
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.